- Trials with a EudraCT protocol (423)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
423 result(s) found for: 5 fluorouracil.
Displaying page 1 of 22.
EudraCT Number: 2018-003436-74 | Sponsor Protocol Number: 01-18/629-15 | Start Date*: 2019-07-10 | |||||||||||
Sponsor Name:Intas Pharmaceuticals Ltd | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-controlled, Three-arm, Parallel Assignment, Multi-Centre, Therapeutic Equivalence Study of Two Fluorouracil 5% Topical Cream Formulations in Adult Pat... | |||||||||||||
Medical condition: Actinic Keratosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001514-20 | Sponsor Protocol Number: CA209-648 | Start Date*: 2017-06-06 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent o... | |||||||||||||
Medical condition: Inoperable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) DK (Completed) PT (Completed) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001018-76 | Sponsor Protocol Number: CA209-649 | Start Date*: 2016-10-10 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Ga... | ||||||||||||||||||
Medical condition: Gastric or Gastroesophageal Junction Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) GR (Completed) PL (Completed) HU (Completed) DE (Completed) PT (Completed) FR (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001338-24 | Sponsor Protocol Number: MK-3475-669(INCB024360-304) | Start Date*: 2017-12-05 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for... | |||||||||||||
Medical condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Temporarily Halted) PT (Trial now transitioned) AT (Prematurely Ended) HU (Completed) PL (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001069-18 | Sponsor Protocol Number: CA224-060 | Start Date*: 2018-09-20 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment... | ||||||||||||||||||
Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NO (Completed) BE (Completed) PL (Completed) AT (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017840-15 | Sponsor Protocol Number: KS-2003-06 | Start Date*: 2004-05-31 |
Sponsor Name:DSC Services, s.r.o. | ||
Full Title: Srovnání účinnosti kapecitabinu (Xeloda) s kontinuálním podáním 5-fluorouracilu v předoperační konkomitantní léčbě s radioterapií u karcinomu rekta | ||
Medical condition: Rectal cancer stage II and III | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000490-21 | Sponsor Protocol Number: SUCCESS | Start Date*: 2005-08-24 |
Sponsor Name:1. Frauenklinik der LMU- Innenstadt | ||
Full Title: Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial SUCCESS-Trial | ||
Medical condition: This is an open-label, multicenter, 2x2 factorial design, randomized controlled, Phase III study comparing the time to recurrence after randomisation in patients with early primary breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000401-91 | Sponsor Protocol Number: iMAGINE | Start Date*: 2020-06-26 | |||||||||||
Sponsor Name:Medizinische Universität Wien | |||||||||||||
Full Title: iMmunoscore Associated decision GuIdance for adjuvaNt chemotherapy and physical Exercise in stage III colon cancer (iMAGINE): a prospective, randomized, open-label, multicenter, phase III clinical ... | |||||||||||||
Medical condition: • Histologically confirmed stage III carcinoma of the colon • Medical need for an standard adjuvant chemotherapy • Suitable to withstand the course of an standard adjuvant chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005141-16 | Sponsor Protocol Number: NL75539.078.20 | Start Date*: 2021-06-23 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study. | |||||||||||||
Medical condition: non-metastatic resectable pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001990-53 | Sponsor Protocol Number: MK-7902-015(E7080-G000-321) | Start Date*: 2020-12-22 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Int... | |||||||||||||
Medical condition: Locally advanced unresectable/metastatic gastroesophageal adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002517-39 | Sponsor Protocol Number: PRODIGE34 | Start Date*: 2014-09-05 |
Sponsor Name:Fédération Francophone de Cancérologie Digestive (FFCD) | ||
Full Title: Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more | ||
Medical condition: Adjuvant treatment in stage III adenocarcinoma of the colon fully resected for patient of 70 years and over | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004896-30 | Sponsor Protocol Number: CA224-051 | Start Date*: 2018-07-06 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS- 986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo i... | ||||||||||||||||||
Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Prematurely Ended) AT (Prematurely Ended) NO (Completed) ES (Prematurely Ended) PL (Completed) NL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003698-41 | Sponsor Protocol Number: MK-3475-048 | Start Date*: 2015-02-19 | |||||||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc. | |||||||||||||||||||||||
Full Title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | |||||||||||||||||||||||
Medical condition: Recurrent/metastatic head and neck squamous cell carcinoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Completed) EE (Completed) LV (Completed) DK (Completed) FI (Completed) AT (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) RO (Ongoing) GR (Completed) DE (Completed) IT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001911-26 | Sponsor Protocol Number: MK-7902-014(E7080-G000-320) | Start Date*: 2021-07-17 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in P... | |||||||||||||
Medical condition: Metastatic squamous cell carcinoma of the esophagus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004408-76 | Sponsor Protocol Number: 3475-585 | Start Date*: 2017-08-25 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase III, Randomized, Double-blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subje... | |||||||||||||
Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) LT (Trial now transitioned) EE (Trial now transitioned) LV (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004675-31 | Sponsor Protocol Number: AMCmedonc17-010 | Start Date*: 2019-11-13 |
Sponsor Name:Academic Medical Center | ||
Full Title: A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on firs... | ||
Medical condition: pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) ES (Ongoing) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005210-18 | Sponsor Protocol Number: EFFIPEC01 | Start Date*: 2021-03-28 | |||||||||||
Sponsor Name:Uppsala University | |||||||||||||
Full Title: EFFIPEC – Efficacy of Hyperthermic Intraperitoneal Chemotherapy Single-arm Phase I study, followed by an open-label, randomized, controlled registry-based Phase III trial | |||||||||||||
Medical condition: Colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000460-24 | Sponsor Protocol Number: TT1-2007 | Start Date*: 2009-04-07 | |||||||||||
Sponsor Name:University of Duisburg-Essen | |||||||||||||
Full Title: Bi-weekly Cetuximab combined with FOLFOX-6 as first-line treatment in metastatic colorectal cancer patients with wild-type k-ras status | |||||||||||||
Medical condition: Histologically proven metastatic colorectal cancer with k-ras wildtyp status | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016019-39 | Sponsor Protocol Number: TPU-S1303 | Start Date*: 2011-02-14 | |||||||||||
Sponsor Name:Taiho Oncology, Inc. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF S-1 AND CISPLATIN COMPARED WITH 5-FU AND CISPLATIN IN PATIENTS WITH METASTATIC DIFFUSE GASTRIC CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAPY | |||||||||||||
Medical condition: Metastatic Diffuse Gastric Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) HU (Completed) GB (Completed) ES (Completed) PT (Completed) EE (Completed) IT (Prematurely Ended) BG (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004048-27 | Sponsor Protocol Number: 849-010 | Start Date*: 2022-02-09 | |||||||||||
Sponsor Name:Mirati Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Stan... | |||||||||||||
Medical condition: Advanced Colorectal Cancer with KRAS G12C Mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
